Candesartan therapy significantly reduced cardiovascular events compared to control (16.3% vs 45.9%, P<0.01) in patients on chronic maintenance haemodialysis.
RCT (n=80)
randomly assigned
Does candesartan reduce cardiovascular events in stable chronic haemodialysis patients without clinical evidence of cardiac disorders?
Candesartan therapy significantly reduces cardiovascular events and mortality in stable chronic hemodialysis patients without prior clinical cardiac disorders.
Absolute Event Rate: 16.3% vs 45.9%
p-value: p=< 0.01
BACKGROUND: Cardiovascular events are the major determinants of the prognosis of patients on chronic haemodialysis. The present study was designed to investigate whether candesartan, an angiotensin II type-1 receptor blocker, reduces the incidence of cardiovascular events in these patients. METHODS: A total of 80 chronic haemodialysis patients (male/female, 47/33; mean age +/- SEM, 61 +/- 1 years) in stable condition and with no clinical evidence of cardiac disorders were enrolled. Patients were randomly assigned candesartan 4-8 mg/day (candesartan group; n = 43) or nothing (control group; n = 37), and followed for 19.4 +/- 1.2 months with as endpoint cardiovascular events such as fatal/nonfatal myocardial infarction, unstable angina pectoris, congestive heart failure, severe arrhythmia and sudden death. RESULTS: Both groups exhibited similar clinical characteristics at baseline. During follow-up, cardiovascular events occurred in seven patients in the candesartan group and 17 in the control group. Kaplan-Meier analysis revealed that cardiovascular events and mortality rates were significantly (P < 0.01) higher in the control group than in the candesartan group (45.9 vs 16.3% and 18.9 vs 0.0%, respectively). CONCLUSIONS: Candesartan therapy significantly reduces cardiovascular events and mortality in patients on chronic maintenance haemodialysis and therefore improves the prognosis of these patients.
Takahashi et al. (Fri,) conducted a rct in chronic haemodialysis (n=80). candesartan vs. nothing (control group) was evaluated on cardiovascular events such as fatal/nonfatal myocardial infarction, unstable angina pectoris, congestive heart failure, severe arrhythmia and sudden death (p=< 0.01). Candesartan therapy significantly reduced cardiovascular events compared to control (16.3% vs 45.9%, P<0.01) in patients on chronic maintenance haemodialysis.